Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Daniel S. Leventhal(Xalud Therapeutics (United States)), José M. Lora(Hospital for Special Surgery)
Cited by 426
Related Papers
Synthetic biology: at the crossroads of genetic engineering and human therapeutics—a Keystone Symposia report
|Annals of the New York Academy of Sciences|2021|10